Form 4: Solid Biosciences CFO Sells Shares for Tax Obligations

Solid Biosciences CFO Kevin Tan reported the acquisition of shares from RSU vesting and a subsequent sale to cover tax withholding, not a discretionary trade.

Summary

• Kevin Tan, CFO & Treasurer of Solid Biosciences Inc. (SLDB), reported transactions involving the company's common stock.
• On January 9, 2026, Tan acquired 11,250 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• Following this, on January 13, 2026, Tan sold 5,704 shares of common stock at a price of $5.27 per share.
• The sale was explicitly stated to cover withholding taxes related to the RSU vesting and was not a discretionary trade, executed under a pre-arranged 10b5-1 plan adopted on August 15, 2024.
• After these transactions, Tan beneficially owns 46,100 shares of Solid Biosciences common stock.
• The reported beneficial ownership also includes 4,152 shares acquired under the Employee Stock Purchase Plan on May 30, 2025, and another 4,152 shares on November 28, 2025.

Sentiment

Score: 6

Explanation: The transaction is neutral to slightly positive. While there's a sale of shares, it's non-discretionary and for tax purposes, which is a routine event for executives. The vesting of RSUs indicates continued long-term incentive alignment.

Positives

• The RSU vesting indicates continued long-term incentive alignment between management and shareholders.
• The sale was non-discretionary, solely for tax purposes, suggesting no negative sentiment from the insider regarding the company's prospects.

Negatives

• A reduction in direct beneficial ownership, even if for tax purposes, decreases the insider's direct stake.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely focused on insider transaction reporting.

Management Comments

• This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.

Industry Context

This filing is a routine insider transaction report and does not provide specific industry context. Insider transactions, particularly non-discretionary ones like this, are common across all industries for executives managing equity compensation and tax obligations.

Comparison to Industry Standards

• This Form 4 filing reports a standard insider transaction (vesting and sell-to-cover) which is a common practice for executives receiving equity compensation across various industries. There are no specific comparable companies or projects mentioned in the filing to assess against industry standards beyond the routine nature of the transaction itself.

Stakeholder Impact

• Shareholders: Minor dilution from RSU conversion, but the sell-to-cover is a routine event. No significant impact on company valuation or strategy.
• Employees: The RSU vesting and ESPP share acquisitions highlight the company's equity compensation programs.

Next Steps

• Future vesting events of the RSUs granted on January 9, 2023, will occur annually until the fourth anniversary.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CFO acquired shares through RSU vesting and subsequently sold a portion to cover tax obligations under a pre-arranged 10b5-1 plan. This is a non-discretionary event and does not reflect a change in the insider's sentiment towards the company's prospects. As such, it provides no new fundamental information to warrant a change in investment recommendation. A 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to buy or sell based on this specific transaction.

Keywords

Solid Biosciences, SLDB, Kevin Tan, Insider Trading, Form 4, Restricted Stock Units, RSU, Stock Sale, Tax Withholding, CFO, Beneficial Ownership, 10b5-1 Plan